Circulating Biomarkers to Identify Responders in Cardiac Cell therapy

Abstract Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as we...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jesse V. Jokerst, Nicholas Cauwenberghs, Tatiana Kuznetsova, Francois Haddad, Timothy Sweeney, Jiayi Hou, Yael Rosenberg-Hasson, Eric Zhao, Robert Schutt, Roberto Bolli, Jay H. Traverse, Carl J. Pepine, Timothy D. Henry, Ivonne H. Schulman, Lem Moyé, Doris A. Taylor, Phillip C. Yang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/47663ea787eb4f74b71588c098542657
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:47663ea787eb4f74b71588c098542657
record_format	dspace
spelling	oai:doaj.org-article:47663ea787eb4f74b71588c0985426572021-12-02T12:30:53ZCirculating Biomarkers to Identify Responders in Cardiac Cell therapy10.1038/s41598-017-04801-72045-2322https://doaj.org/article/47663ea787eb4f74b71588c0985426572017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-04801-7https://doaj.org/toc/2045-2322Abstract Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76–94% elevated) than non-responders. Several biomarkers had values that differed significantly (P < 0.05) between responders and non-responders including stem cell factor, platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis and found multiple biomarkers with values areas under the curve >0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers.Jesse V. JokerstNicholas CauwenberghsTatiana KuznetsovaFrancois HaddadTimothy SweeneyJiayi HouYael Rosenberg-HassonEric ZhaoRobert SchuttRoberto BolliJay H. TraverseCarl J. PepineTimothy D. HenryIvonne H. SchulmanLem MoyéDoris A. TaylorPhillip C. YangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jesse V. Jokerst Nicholas Cauwenberghs Tatiana Kuznetsova Francois Haddad Timothy Sweeney Jiayi Hou Yael Rosenberg-Hasson Eric Zhao Robert Schutt Roberto Bolli Jay H. Traverse Carl J. Pepine Timothy D. Henry Ivonne H. Schulman Lem Moyé Doris A. Taylor Phillip C. Yang Circulating Biomarkers to Identify Responders in Cardiac Cell therapy
description	Abstract Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76–94% elevated) than non-responders. Several biomarkers had values that differed significantly (P < 0.05) between responders and non-responders including stem cell factor, platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis and found multiple biomarkers with values areas under the curve >0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers.
format	article
author	Jesse V. Jokerst Nicholas Cauwenberghs Tatiana Kuznetsova Francois Haddad Timothy Sweeney Jiayi Hou Yael Rosenberg-Hasson Eric Zhao Robert Schutt Roberto Bolli Jay H. Traverse Carl J. Pepine Timothy D. Henry Ivonne H. Schulman Lem Moyé Doris A. Taylor Phillip C. Yang
author_facet	Jesse V. Jokerst Nicholas Cauwenberghs Tatiana Kuznetsova Francois Haddad Timothy Sweeney Jiayi Hou Yael Rosenberg-Hasson Eric Zhao Robert Schutt Roberto Bolli Jay H. Traverse Carl J. Pepine Timothy D. Henry Ivonne H. Schulman Lem Moyé Doris A. Taylor Phillip C. Yang
author_sort	Jesse V. Jokerst
title	Circulating Biomarkers to Identify Responders in Cardiac Cell therapy
title_short	Circulating Biomarkers to Identify Responders in Cardiac Cell therapy
title_full	Circulating Biomarkers to Identify Responders in Cardiac Cell therapy
title_fullStr	Circulating Biomarkers to Identify Responders in Cardiac Cell therapy
title_full_unstemmed	Circulating Biomarkers to Identify Responders in Cardiac Cell therapy
title_sort	circulating biomarkers to identify responders in cardiac cell therapy
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/47663ea787eb4f74b71588c098542657
work_keys_str_mv	AT jessevjokerst circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT nicholascauwenberghs circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT tatianakuznetsova circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT francoishaddad circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT timothysweeney circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT jiayihou circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT yaelrosenberghasson circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT ericzhao circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT robertschutt circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT robertobolli circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT jayhtraverse circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT carljpepine circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT timothydhenry circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT ivonnehschulman circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT lemmoye circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT dorisataylor circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy AT phillipcyang circulatingbiomarkerstoidentifyrespondersincardiaccelltherapy
_version_	1718394275527393280

Circulating Biomarkers to Identify Responders in Cardiac Cell therapy

Ejemplares similares